MedTrace Logo

A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine

NCT02472548 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-02-05

No results posted yet for this study

Summary

Administration of DPX-RSV(A), a Respiratory Syncytial Virus vaccine containing Respiratory Syncytial Virus (RSV) SHe antigen and DepoVaxTM adjuvant to healthy adults ≥50-64 years of age.

Conditions

Interventions

BIOLOGICAL

DPX-RSV(A)

Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.

BIOLOGICAL

RSV(A)-Alum

Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.

OTHER

Placebo

Normal saline (0.9 % sodium chloride) will be administered intramuscularly.

Sponsors & Collaborators

  • ImmunoVaccine Technologies, Inc. (IMV Inc.)

    collaborator INDUSTRY

  • Dalhousie University

    lead OTHER

Principal Investigators

  • Joanne M Langley, MD, MSc, FRCPC · Dalhousie University, IWK Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-03-14
Completion
2017-03-14

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02472548 on ClinicalTrials.gov